<DOC>
	<DOCNO>NCT02397239</DOCNO>
	<brief_summary>Protocol title : Comparison cost-effectiveness continuation maintenance therapy six cycle pemetrexed versus pemetrexed disease progression metastatic non-squamous non-small-cell lung cancer ( NSCLC ) Study design : An open-labelled , randomize , phase 2 trial Indication : Patients stage IV non-squamous NSCLC , Eastern Cooperative Oncology Group ( ECOG ) performance status 0-1 , receive first-line second-line chemotherapy pemetrexed plus platinum 4 cycle Treatment : Maintenance pemetrexed 500 mg/m2 every 3 week six cycle versus disease progression Objectives : Primary endpoint : 1 . Cost-effectiveness intention-to-treat population Secondary endpoint : 1 . Progression-free survival 2 . Overall survival 3 . Quality-of-life ( QoL ) 4 . Quality-adjusted progression-free survival ( QA-PFS ) 5 . Quality-adjusted life expectancy ( QALE ) 6 . Tumor response rate 7 . Adverse event Planned sample size : 61 patient arm ; total 122 patient Total number site : 1 site Duration patient enrollment : 3 year</brief_summary>
	<brief_title>Comparison Cost-effectiveness Continuation Maintenance Therapy With Six Cycles Pemetrexed Versus Pemetrexed Until Disease Progression Metastatic Non-squamous Non-small-cell Lung Cancer</brief_title>
	<detailed_description>Inclusion criterion : 1 . Males females ≥ 20 year age 2 . ECOG performance status 0-1 3 . Histologically cytologically verify non-squamous NSCLC 4 . Stage IV disease , define American Joint Committee Cancer 7th edition staging , prior first-line second-line chemotherapy pemetrexed plus platinum 5 . At least one measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 6 . Completion 4 cycle first-line second-line chemotherapy pemetrexed plus platinum document radiographic evidence complete partial tumor response stable disease RECIST 1.1 7 . Adequate organ function , include following : Bone marrow : Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 10.0 g/dL Hepatic : Total bilirubin ≤ 1.5 x upper normal limit ( UNL ) Aspartate aminotransferase ( AST ) ≤ 3.0 x UNL ( ≤ 5.0 x UNL liver metastasis ) Alanine aminotransferase ( ALT ) ≤ 3.0 x UNL ( ≤ 5.0 x UNL liver metastasis ) Renal : Creatinine ≤ 1.5 mg/dL men , ≤ 1.4 mg/dL woman Estimated glomerular filtration rate ≥ 60 mL/min 8 . Estimated life expectancy least 6 month 9 . Ability comply study follow-up procedure 10 . Signed informed consent document Exclusion criterion : 1 . Squamous cell and/or mixed small-cell , non-small-cell histology 2 . Prior participation investigational drug study within 4 week 3 . Prior malignancy NSCLC , except remain disease-free ≥ 3 year curative treatment , non-melanoma skin cancer situ cervical cancer 4 . Serious concomitant systemic disorder , acute recent myocardial infarction ( &lt; 6 month enrollment ) , congestive heart failure New York Heart Association functional class II~IV , frequent exacerbation chronic obstructive pulmonary disease ( ≥ 2 hospitalization per year ) , recent cerebrovascular disease ( &lt; 6 month enrollment ) 5 . Active uncontrolled infection HIV infection 6 . Current planned pregnancy , breast feeding woman 7 . Symptomatic central nervous system metastasis unless patient complete successful local therapy corticosteroid ≥ 4 week 8 . Concurrent administration antitumor therapy include chemotherapy , target therapy , immunotherapy , hormone therapy 9 . Psychiatric disorder would compromise patient 's compliance decision Criteria evaluation : QoL : QoL measure use EuroQol 5-dimensional questionnaire ( EQ-5D ) , World Health Organization Quality-of-Life , brief version ( WHOQOL-BREF ) , European Organization Research Treatment Cancer ( EORTC ) questionnaires . Efficacy : Tumor response rate determine RECIST 1.1 . Data progression-free survival overall survival collect subject . QA-PFS QALE : Investigators adjust progression-free survival utility value QoL measure EQ-5D obtain QA-PFS . In addition , investigator extrapolate survival function lifetime base survival ratio patient age- sex-matched referent simulate life table Taiwan . After adjust lifetime survival utility value QoL , QALE also estimate use quality-adjusted life-year ( QALY ) unit . Cost-effectiveness : The monthly healthcare expenditure , include National Health Insurance-reimbursed out-of-pocket direct medical cost , obtain reimbursement database National Cheng Kung University Hospital . These value multiply correspond survival probability calculate lifetime cost cost progression-free period . Hence , costs/life-year costs/QALY obtain comparison cost-effectiveness . Adverse event : Safety parameter include laboratory adverse event ( e.g. , anemia , leukopenia , neutropenia , thrombocytopenia , creatinine , AST , ALT ) non-laboratory adverse event ( e.g. , fatigue , nausea , vomit , mucositis/stomatitis , anorexia , diarrhea , constipation , infection , febrile neutropenia , pain , sensory neuropathy , rash , edema , watery eye ) . Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 use grade toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Males females ≥ 20 year age 2 . ECOG performance status 01 3 . Histologically cytologically verify nonsquamous NSCLC 4 . Stage IV disease , define American Joint Committee Cancer 7th edition staging , prior firstline secondline chemotherapy pemetrexed plus platinum 5 . At least one measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 6 . Completion 4 cycle firstline secondline chemotherapy pemetrexed plus platinum document radiographic evidence complete partial tumor response stable disease RECIST 1.1 7 . Adequate organ function , include following : Bone marrow : Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 10.0 g/dL Hepatic : Total bilirubin ≤ 1.5 x upper normal limit ( UNL ) Aspartate aminotransferase ( AST ) ≤ 3.0 x UNL ( ≤ 5.0 x UNL liver metastasis ) Alanine aminotransferase ( ALT ) ≤ 3.0 x UNL ( ≤ 5.0 x UNL liver metastasis ) Renal : Creatinine ≤ 1.5 mg/dL men , ≤ 1.4 mg/dL woman Estimated glomerular filtration rate ≥ 60 mL/min 8 . Estimated life expectancy least 6 month 9 . Ability comply study followup procedure 10 . Signed informed consent document 1 . Squamous cell and/or mixed smallcell , nonsmallcell histology 2 . Prior participation investigational drug study within 4 week 3 . Prior malignancy NSCLC , except remain diseasefree ≥ 3 year curative treatment , nonmelanoma skin cancer situ cervical cancer 4 . Serious concomitant systemic disorder , acute recent myocardial infarction ( &lt; 6 month enrollment ) , congestive heart failure New York Heart Association functional class II~IV , frequent exacerbation chronic obstructive pulmonary disease ( ≥ 2 hospitalization per year ) , recent cerebrovascular disease ( &lt; 6 month enrollment ) 5 . Active uncontrolled infection HIV infection 6 . Current planned pregnancy , breast feeding woman 7 . Symptomatic central nervous system metastasis unless patient complete successful local therapy corticosteroid ≥ 4 week 8 . Concurrent administration antitumor therapy include chemotherapy , target therapy , immunotherapy , hormone therapy 9 . Psychiatric disorder would compromise patient 's compliance decision</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>